This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Integer Holdings posts strong Q3 results with earnings and revenue beat, but shares plunge on a softer 2026 growth outlook.
PODDNegative Net Change PAHCPositive Net Change VCYTPositive Net Change ITGRNegative Net Change
earnings medical medical-devices
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
by Zacks Equity Research
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
MASINegative Net Change FMSPositive Net Change MMSINegative Net Change WSTNegative Net Change
medical medical-devices
HCA Q3 Earnings Beat Estimates on Rising Inpatient Surgery Cases
by Zacks Equity Research
HCA Healthcare's Q3 earnings rise 42% y/y on stronger patient volumes and rising inpatient surgeries, prompting management to lift its 2025 outlook.
UHSPositive Net Change HCAPositive Net Change ANIPNegative Net Change EHCNegative Net Change
earnings finance medical
Community Health Q3 Earnings Beat on Rising Same-Store Admissions
by Zacks Equity Research
CYH's Q3 earnings surge on higher same-store admissions, cost cuts and a stronger payor mix, swinging to a $171M profit from a loss last year.
UHSPositive Net Change CYHPositive Net Change ANIPNegative Net Change EHCNegative Net Change
earnings finance medical
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
by Sundeep Ganoria
Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.
NVONegative Net Change LLYPositive Net Change GPCRNegative Net Change
biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Amazon.com, Wells Fargo, Amgen, IDT and Village Super Market
by Zacks Equity Research
Zacks spotlights Amazon, Wells Fargo, Amgen, IDT and Village Super Market in its latest Analyst Blog, showcasing diverse growth drivers and risks.
AMZNPositive Net Change WFCPositive Net Change AMGNNegative Net Change IDTPositive Net Change VLGEANegative Net Change
finance medical retail utilities
Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs
by Aparajita Dutta
Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.
JNJNegative Net Change LLYPositive Net Change XLVPositive Net Change IYHPositive Net Change VHTPositive Net Change GEHCPositive Net Change
etfs medical
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
by Ekta Bagri
Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength
BMYNo Net Change PFEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Best Momentum Stocks to Buy for Oct. 24
by Zacks Equity Research
ASM, IGC and RY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 24, 2025.
RYPositive Net Change IGCPositive Net Change ASMNegative Net Change
medical
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
NVSNegative Net Change LLYPositive Net Change INCYPositive Net Change EXASNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
by Zacks Equity Research
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
REGNPositive Net Change ALNYNegative Net Change NVSNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
UnitedHealth Recovers Its Rhythm Before Q3 Earnings: Time to Buy?
by Kaibalya Pravo Dey
UNH's Q3 results hinge on premium growth and Optum gains amid rising costs and margin pressure.
UNHPositive Net Change HUMNegative Net Change MOHPositive Net Change
earnings-outlook earnings-preview healthcare hmo insurance insurance-premium medical
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
by Sundeep Ganoria
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Will SYK's Q3 Results Reflect MedSurg Strength & Rebound in Orthopaedics?
by Zacks Equity Research
Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.
SYKNegative Net Change MCKPositive Net Change EWNegative Net Change GMEDNegative Net Change
medical medical-devices
Pharma, Specialty Units Likely to Drive Cardinal Health's Q1 Earnings
by Zacks Equity Research
CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.
BDXNegative Net Change CAHPositive Net Change MCKPositive Net Change CORPositive Net Change
medical medical-devices
Here's How Charles River Stock Is Placed Ahead of Q3 Earnings
by Zacks Equity Research
CRL heads into Q3 earnings with steady RMS growth but faces DSA headwinds from tight biotech budgets.
CRLPositive Net Change ANIPNegative Net Change EXASNegative Net Change EHCNegative Net Change
earnings medical medical-devices
5 Stocks With Robust Sales Growth to Buy Amid a Challenging Backdrop
by Swayta Shah
Amid market volatility, strong sales growth makes stocks like Lamb Weston, UHS, FirstEnergy, NetEase and JPMorgan compelling buys.
JPMPositive Net Change FEPositive Net Change UHSPositive Net Change NTESNegative Net Change LWPositive Net Change
computers consumer-staples fin-tech finance internet medical tech-stocks utilities
Top Research Reports for Amazon.com, Wells Fargo & Amgen
by Mark Vickery
Amazon's AI push, Wells Fargo's post-cap growth, and Amgen's new drug momentum headline Zacks' latest top analyst reports.
AMZNPositive Net Change WFCPositive Net Change AMXNegative Net Change AMGNNegative Net Change MMCNegative Net Change IDTPositive Net Change VLGEANegative Net Change RTXNegative Net Change
finance medical retail utilities
Buy the Post-Earnings Surge in Intuitive Surgical (ISRG) Stock?
by Shaun Pruitt
Intuitive Surgical's stock has been on a tear since the medical pioneer exceeded Q3 expectations on Tuesday and provided positive guidance that left investors hyped about rising demand for robotic-assisted surgical systems.
ISRGNegative Net Change
earnings investing large-cap medical medical-devices robotics
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
by Zacks Equity Research
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
ALNYNegative Net Change ALKSNegative Net Change VKTXPositive Net Change HOWLPositive Net Change
biotechs earnings medical
Here's Why You Should Add OPKO Health Stock to Your Portfolio
by Zacks Equity Research
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
MASINegative Net Change MMSINegative Net Change WSTNegative Net Change OPKNegative Net Change
medical medical-devices
Can Sustained Strength in Water Drive ECL Stock Before Q3 Earnings?
by Zacks Equity Research
Ecolab's Water and Pest units show strength ahead of third-quarter 2025, but softness in Paper and macroeconomic headwinds may weigh on growth.
ECLPositive Net Change ESIPositive Net Change COIHYPositive Net Change SYIEYPositive Net Change
earnings medical medical-devices
Molina Healthcare Q3 Earnings Miss Estimates on Rising Expenses
by Zacks Equity Research
MOH's Q3 earnings plunge 69% as rising medical and administrative costs offset higher premiums and revenue gains.
MOHPositive Net Change EVRPositive Net Change ANIPNegative Net Change EXASNegative Net Change
earnings finance medical
WST Stock Up on Q3 Earnings Beat, EPS View Raised on Demand & FX Benefit
by Zacks Equity Research
West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.
BSXNegative Net Change MASINegative Net Change MMSINegative Net Change WSTNegative Net Change
earnings medical medical-devices
Will Lower Patient Days Affect Tenet Healthcare's Q3 Earnings?
by Zacks Equity Research
THC's third-quarter results may show profit growth despite lower patient days and mixed hospital trends.
THCPositive Net Change SEMPositive Net Change NVSTPositive Net Change ERASPositive Net Change
earnings medical